意大利“晚邮报”和“团结报”1985年9月12日报道,米兰“玛利奥·纳格利”药物研究所(ISTITUTO DI RICERCHE FARM-ACOLOGICHE“MARIO NEGRI”)和医院心脏病学医生协会共同组织的意大利链激酶治疗心肌梗塞研究组经过长期研究,证明用...意大利“晚邮报”和“团结报”1985年9月12日报道,米兰“玛利奥·纳格利”药物研究所(ISTITUTO DI RICERCHE FARM-ACOLOGICHE“MARIO NEGRI”)和医院心脏病学医生协会共同组织的意大利链激酶治疗心肌梗塞研究组经过长期研究,证明用链激酶(STREPTOCHINASI)治疗心肌梗塞效果良好,住院患者死亡率大大降低。展开更多
Plasminogen activator inhibitor-1(PAI-1)is the primary inhibitor of urinary-type and tissue-type plasmino-gen activators and a key regulator of fibrinolysis.PAI-1 also regulates the function of vascular cells,includin...Plasminogen activator inhibitor-1(PAI-1)is the primary inhibitor of urinary-type and tissue-type plasmino-gen activators and a key regulator of fibrinolysis.PAI-1 also regulates the function of vascular cells,includingvascular smooth muscle cells(VSMCs).展开更多
文摘意大利“晚邮报”和“团结报”1985年9月12日报道,米兰“玛利奥·纳格利”药物研究所(ISTITUTO DI RICERCHE FARM-ACOLOGICHE“MARIO NEGRI”)和医院心脏病学医生协会共同组织的意大利链激酶治疗心肌梗塞研究组经过长期研究,证明用链激酶(STREPTOCHINASI)治疗心肌梗塞效果良好,住院患者死亡率大大降低。
文摘Plasminogen activator inhibitor-1(PAI-1)is the primary inhibitor of urinary-type and tissue-type plasmino-gen activators and a key regulator of fibrinolysis.PAI-1 also regulates the function of vascular cells,includingvascular smooth muscle cells(VSMCs).